Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have shown promising results in advanced NSCLC and prolonged patient survival. This evidence concerns the gene CD274 and non-small cell lung carcinoma.